GHRS trades 43.8% below Wall Street's consensus target of $40.57.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GHRS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, GH Research PLC (GHRS) has a Wall Street consensus price target of $40.57, based on estimates from 9 covering analysts. With the stock currently trading at $28.22, this represents a potential upside of +43.8%. The company has a market capitalization of $1.93B.
Analyst price targets range from a low of $32.00 to a high of $65.00, representing a 81% spread in expectations. The median target of $39.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GHRS trades at a trailing P/E of -35.7x. Analysts expect EPS to grow -53.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CMPSCOMPASS Pathways plc | $1.4B | $14.82 | $18.57 | +25.3% | Buy | — | 13 |
ATAIAtai Beckley N.V | $1.9B | $5.29 | $12.00 | +126.8% | Buy | — | 4 |
MNMDMind Medicine (MindMed) Inc. | $2.0B | $20.69 | $20.00 | -3.3% | Buy | — | 1 |
CYBNCybin Inc. | $304M | $6.09 | — | — | Buy | — | 4 |
NRXPNRx Pharmaceuticals, Inc. | $64M | $3.73 | — | — | — | — | — |
ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.32 | $33.67 | +33.0% | Buy | 65.1x | 37 |
AXSMAxsome Therapeutics, Inc. | $12.4B | $241.67 | $262.38 | +8.6% | Buy | — | 26 |
INVAInnoviva, Inc. | $1.7B | $23.57 | $37.00 | +57.0% | Buy | 6.6x | 10 |
ALTOAlto Ingredients, Inc. | $401M | $5.19 | $10.00 | +92.7% | Buy | 12.1x | 2 |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
Quick answers to the most common questions about buying GHRS stock.
The consensus Wall Street price target for GHRS is $40.57, representing 43.8% upside from the current price of $28.22. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
GHRS has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $40.57 implies 43.8% upside from current levels.
GHRS's current price is $28.22 with a consensus target of $40.57 (43.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $65 for GHRS, while the most conservative target is $32. The consensus of $40.57 represents the median expectation. These targets typically reflect 12-month expectations.
GHRS is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GHRS stock forecast based on 9 Wall Street analysts shows a consensus price target of $40.57, with estimates ranging from $32 (bear case) to $65 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on GHRS, with a "Buy" consensus rating and $40.57 price target (43.8% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GHRS analyst price targets range from $32 to $65, a 81% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $40.57 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.